Tag: GlobeNewswire

HUNTSVILLE, Ala., Oct. 06, 2026 (GLOBE NEWSWIRE) — Octave Intelligence plc (Nasdaq New York: OCTV and Nasdaq Stockholm: OCTV SDB), a global leader in software for the world’s mission critical facilities and infrastructure, will release its third quarter 2026 financial results on Thursday, November 12, 2026, at approximately 7:00 a.m. Eastern Time.

The company will host a conference call that same day to discuss its results and business outlook at 8:00 a.m. Eastern Time. To register for the live event, please visit: https://octave-q3-earnings-call-2026.open-exchange.net/

A live webcast of the conference call and the financial results press release will be accessible from the Octave investor relations website at investors.octave.com. A webcast replay of the call will be available at investors.octave.com.

About Octave: Octave provides mission-critical software that empowers organizations to make informed decisions across every stage of the asset lifecycle — Design, Build, Operate and Protect — where performance, safety, and reliability are non-negotiable and failure is not an option.

Turning complex operational data into actionable intelligence, Octave connects expertise, real-world conditions and enterprise-scale insight to improve performance, resilience and incident response where it matters most.

Octave has approximately 7,200 employees in 45 countries. Learn more at octave.com and follow us on LinkedIn.

Octave Investor Contact: Elizabeth Chwalk, VP, Investor Relations, elizabeth.chwalk@octave.com  

Octave Media Contact: media@octave.com

– Acquired Significantly Below Replacement Cost –
– 2026 Year-to-Date Investments Total $439 Million –

WINTER PARK, Fla., Oct. 06, 2026 (GLOBE NEWSWIRE) — CTO Realty Growth, Inc. (NYSE: CTO) (the “Company” or “CTO”) today announced the acquisition of Summit Woods Crossing (the “Property”), a 545,000-square-foot open-air power center situated on 57 acres in the Kansas City, Missouri metro area, for a purchase price of $103.0 million, or $189 per square foot.

“Summit Woods Crossing is a market-dominant, open-air center that is nearly 100% occupied and strengthens our presence in Kansas City,” said John P. Albright, President and Chief Executive Officer of CTO Realty Growth. “The acquisition reflects what we look for in an investment: a purchase price well below replacement cost, an attractive yield, and in-place rents below market. It brings our year-to-date investment volume, inclusive of both property and structured investments, to $439 million at a blended initial cash yield of approximately 9.0%, and has helped grow our portfolio 30% this year, from 5.5 million to 7.1 million square feet.”

Summit Woods Crossing is located in Lee’s Summit, Missouri, approximately twenty miles southeast of Kansas City. Lee’s Summit is consistently ranked as one of the best places to live in America, offering superior quality life, a vibrant downtown, and award-winning schools. The Property is anchored by Lowe’s, Kohl’s, Best Buy, TJ Maxx, and Total Wine, with an on-site SuperTarget not owned by the Company. Summit Woods Crossing attracts approximately 7.3 million visits annually and has a population of 113,000 and an average household income of $123,000 within a five-mile radius.

About CTO Realty Growth, Inc.

CTO Realty Growth, Inc. owns and operates high-quality, open-air shopping centers located primarily in the higher growth Southeast and Southwest markets of the United States. CTO also externally manages and owns a meaningful interest in Alpine Income Property Trust, Inc. (NYSE: PINE), a publicly traded net lease REIT.

We encourage you to review our most recent investor presentation and supplemental financial information, which is available on our website at www.ctoreit.com.

Safe Harbor

Certain statements contained in this press release (other than statements of historical fact) are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements can typically be identified by words such as “outlook,” “believe,” “estimate,” “expect,” “intend,” “anticipate,” “will,” “could,” “may,” “should,” “plan,” “potential,” “predict,” “forecast,” “project,” and similar expressions, as well as variations or negatives of these words. Examples of forward-looking statements in this press release include, without limitation, statements regarding the Company’s acquisition of the Property at a discount to replacement cost.

Although forward-looking statements are made based upon management’s present expectations and beliefs concerning future developments and their potential effect upon the Company, a number of factors could cause the Company’s actual results to differ materially from those set forth in the forward-looking statements. Such factors may include, but are not limited to: the Company’s ability to remain qualified as a REIT; the Company’s exposure to U.S. federal and state income tax law changes, including changes to the REIT requirements; general adverse economic and real estate conditions; macroeconomic and geopolitical factors, including but not limited to inflationary pressures, interest rate volatility, ongoing geopolitical war, distress in the banking sector, and global supply chain disruptions; credit risk associated with the Company investing in commercial loans, preferred equity, and similarly structured investments; the ultimate geographic spread, severity and duration of pandemics such as the COVID-19 Pandemic and its variants, actions that may be taken by governmental authorities to contain or address the impact of such pandemics, and the potential negative impacts of such pandemics on the global economy and the Company’s financial condition and results of operations; the inability of major tenants or borrowers to continue paying their rent or obligations due to bankruptcy, insolvency or a general downturn in their business; the loss or failure, or decline in the business or assets of PINE; the completion of 1031 exchange transactions; the availability of investment properties that meet the Company’s investment goals and criteria; the uncertainties associated with obtaining required governmental permits and satisfying other closing conditions for planned acquisitions and sales; and the uncertainties and risk factors discussed in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and other risks and uncertainties discussed from time to time in the Company’s filings with the U.S. Securities and Exchange Commission.

There can be no assurance that future developments will be in accordance with management’s expectations or that the effect of future developments on the Company will be those anticipated by management. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances.

Contact:
Investor Relations
ir@ctoreit.com

– Acquired Significantly Below Replacement Cost –
– 2026 Year-to-Date Investments Total $439 Million –

WINTER PARK, Fla., Oct. 06, 2026 (GLOBE NEWSWIRE) — CTO Realty Growth, Inc. (NYSE: CTO) (the “Company” or “CTO”) today announced the acquisition of Summit Woods Crossing (the “Property”), a 545,000-square-foot open-air power center situated on 57 acres in the Kansas City, Missouri metro area, for a purchase price of $103.0 million, or $189 per square foot.

“Summit Woods Crossing is a market-dominant, open-air center that is nearly 100% occupied and strengthens our presence in Kansas City,” said John P. Albright, President and Chief Executive Officer of CTO Realty Growth. “The acquisition reflects what we look for in an investment: a purchase price well below replacement cost, an attractive yield, and in-place rents below market. It brings our year-to-date investment volume, inclusive of both property and structured investments, to $439 million at a blended initial cash yield of approximately 9.0%, and has helped grow our portfolio 30% this year, from 5.5 million to 7.1 million square feet.”

Summit Woods Crossing is located in Lee’s Summit, Missouri, approximately twenty miles southeast of Kansas City. Lee’s Summit is consistently ranked as one of the best places to live in America, offering superior quality life, a vibrant downtown, and award-winning schools. The Property is anchored by Lowe’s, Kohl’s, Best Buy, TJ Maxx, and Total Wine, with an on-site SuperTarget not owned by the Company. Summit Woods Crossing attracts approximately 7.3 million visits annually and has a population of 113,000 and an average household income of $123,000 within a five-mile radius.

About CTO Realty Growth, Inc.

CTO Realty Growth, Inc. owns and operates high-quality, open-air shopping centers located primarily in the higher growth Southeast and Southwest markets of the United States. CTO also externally manages and owns a meaningful interest in Alpine Income Property Trust, Inc. (NYSE: PINE), a publicly traded net lease REIT.

We encourage you to review our most recent investor presentation and supplemental financial information, which is available on our website at www.ctoreit.com.

Safe Harbor

Certain statements contained in this press release (other than statements of historical fact) are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements can typically be identified by words such as “outlook,” “believe,” “estimate,” “expect,” “intend,” “anticipate,” “will,” “could,” “may,” “should,” “plan,” “potential,” “predict,” “forecast,” “project,” and similar expressions, as well as variations or negatives of these words. Examples of forward-looking statements in this press release include, without limitation, statements regarding the Company’s acquisition of the Property at a discount to replacement cost.

Although forward-looking statements are made based upon management’s present expectations and beliefs concerning future developments and their potential effect upon the Company, a number of factors could cause the Company’s actual results to differ materially from those set forth in the forward-looking statements. Such factors may include, but are not limited to: the Company’s ability to remain qualified as a REIT; the Company’s exposure to U.S. federal and state income tax law changes, including changes to the REIT requirements; general adverse economic and real estate conditions; macroeconomic and geopolitical factors, including but not limited to inflationary pressures, interest rate volatility, ongoing geopolitical war, distress in the banking sector, and global supply chain disruptions; credit risk associated with the Company investing in commercial loans, preferred equity, and similarly structured investments; the ultimate geographic spread, severity and duration of pandemics such as the COVID-19 Pandemic and its variants, actions that may be taken by governmental authorities to contain or address the impact of such pandemics, and the potential negative impacts of such pandemics on the global economy and the Company’s financial condition and results of operations; the inability of major tenants or borrowers to continue paying their rent or obligations due to bankruptcy, insolvency or a general downturn in their business; the loss or failure, or decline in the business or assets of PINE; the completion of 1031 exchange transactions; the availability of investment properties that meet the Company’s investment goals and criteria; the uncertainties associated with obtaining required governmental permits and satisfying other closing conditions for planned acquisitions and sales; and the uncertainties and risk factors discussed in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and other risks and uncertainties discussed from time to time in the Company’s filings with the U.S. Securities and Exchange Commission.

There can be no assurance that future developments will be in accordance with management’s expectations or that the effect of future developments on the Company will be those anticipated by management. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances.

Contact:
Investor Relations
ir@ctoreit.com

Martela Corporation, stock exchange release, October 6, 2026 at 13:45 p.m. (EEST)

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO, OR TO ANY PERSON LOCATED OR RESIDENT IN, THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, NEW ZEALAND, JAPAN, SINGAPORE, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

The final results of Martela Corporation’s (“Martela” or the “Company”) directed share issue (the “Share Issue”) show that a total of 15,907,707 subscriptions for new shares of the Company corresponding to the existing series A shares, representing the Company’s sole series of shares following the combination of share series (the “Offer Shares“) were made in the Share Issue, corresponding to approximately 89 per cent of the 17,777,777 Offer Shares offered in the Share Issue. The subscription price in the Share Issue was EUR 0.45 per Offer Share. Martela receives gross proceeds of approximately EUR 7.2 million from the Share Issue.

Martela’s Board of Directors has today approved the subscriptions made in the Share Issue, and allocated the Offer Shares to be issued, in accordance with the terms and conditions of the Share Issue. As a result of the Share Issue and the combination of share series and the related directed share issue without consideration, as previously disclosed by the Company, the total number of shares in Martela will increase by a maximum of 16,058,907 from 4,639,212 to a maximum of 20,698,119 provided that the combination of the Company’s share series is registered with the Trade Register and the directed share issue without consideration is carried out at its maximum amount, i.e. 151,200 shares. The Offer Shares issued in the Share Issue amount to approximately 77 per cent of all shares in Martela following the Share Issue provided that the combination of share series is registered with the Trade Register.

The Offer Shares will be registered with the Finnish Trade Register maintained by the Finnish Patent and Registration Office on or about 12 October 2026. Trading in the Offer Shares on Nasdaq Helsinki Ltd is estimated to commence on 13 October 2026. The Offer Shares carry the right to dividends and other shareholder rights once the Offer Shares have been registered with the Trade Register. Following the registration of the combination of the share series with the Trade Register on or about 12 October 2026, the Offer Shares carry the same rights as the Company’s other shares.

Advisors

Aktia Alexander Corporate Finance Oy is acting as Martela’s financial advisor and as the Lead Manager of the Share Issue. Castrén & Snellman Attorneys Ltd is acting as Martela’s legal advisor.

MARTELA CORPORATION
BOARD OF DIRECTORS

FOR FURTHER INFORMATION, PLEASE CONTACT:

CEO, Panu Ala-Nikkola
tel +358 50 502 4728

CFO, Henri Berg
tel +358 40 836 5464

Chairman of the Board, Tapio Pajuharju
tel +358 50 5774 200

DISTRIBUTION:

NASDAQ Helsinki, key news media, www.martela.com

MARTELA CORPORATION:

Martela is a Nordic leader specialising in user-centric working and learning environments. With over 80 years of experience, we create the best places to work and offer our customers the Martela Lifecycle solutions which combine furniture and related services into a seamless whole.

IMPORTANT NOTICE:

The distribution of this release may be restricted by law and persons into whose possession any document or other information referred to herein comes should inform themselves about and observe any such relevant legal restrictions. The information contained herein is not for release, publication or distribution, directly or indirectly, in or into the United States, Australia, Canada, Hong Kong, New Zealand, Japan, Singapore, South Africa or any other jurisdiction in which the release, publication or distribution would be unlawful. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction. This release is not directed to, and is not intended for release, publication or distribution to or use by, any person or entity that is a citizen or resident of, or is located in, any locality, state, country or other jurisdiction where such release, distribution, publication, availability or use would violate law or regulation or which would require any registration or licensing within such jurisdiction.

This release does not constitute a prospectus as defined in the Prospectus Regulation nor a document containing the information set out in Annex IX of the Prospectus Regulation and, as such, it does not constitute or form part of, and should not be construed as, an offer to sell, or a solicitation or invitation of any offer to buy, acquire or subscribe for, any securities or an inducement to enter into investment activity in relation to any securities.

No part of this release, nor the fact of its release, publication or distribution, should form the basis of, or be relied on in connection with, any contract or commitment or investment decision whatsoever. No representation, warranty or undertaking, expressed or implied, is made as to, and no reliance should be placed on, the pertinence, accuracy, completeness or correctness of the information or the opinions contained herein. Neither the Company nor any of its respective affiliates, advisors or representatives or any other person shall have any liability whatsoever (in negligence or otherwise) for any loss, however arising, from any use of this release or its contents or otherwise arising in connection with this release. Each person must rely on their own examination and analysis of the Company, its subsidiaries, its securities and the transactions, including the merits and risks involved.

Aktia Alexander Corporate Finance Oy acts exclusively for the Company and no one else in connection with the arrangement. Aktia Alexander Corporate Finance Oy does not regard any other person as its client in relation to the arrangement. Aktia Alexander Corporate Finance Oy is not responsible to anyone other than the Company for providing the protections afforded to its clients, nor for giving advice in relation to the arrangement or any transaction or arrangement referred to herein.

This release includes forward-looking statements. These statements may not be based on historical facts, but are statements about future expectations. When used in this release, the words “aims,” “anticipates,” “assumes,” “believes,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “should,” “will,” “would” and similar expressions as they relate to the Company and the transactions identify certain of these forward-looking statements. Other forward-looking statements can be identified in the context in which the statements are made. These forward-looking statements are based on present plans, estimates, projections and expectations and are not guarantees of future performance. They are based on certain expectations, which, even though they seem to be reasonable at present, may turn out to be incorrect. Such forward-looking statements are based on assumptions and are subject to various risks and uncertainties. Readers should not rely on these forward-looking statements. Numerous factors may cause the actual results of operations or financial condition of the Company to differ materially from those expressed or implied in the forward-looking statements. Neither the Company nor any of its affiliates, advisors, representatives or any other person undertakes any obligation to review, confirm or to publicly release any revisions to any forward-looking statements to reflect events that occur or circumstances that arise following the date of this release.

Martela Corporation, stock exchange release, October 6, 2026 at 13:45 p.m. (EEST)

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO, OR TO ANY PERSON LOCATED OR RESIDENT IN, THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, NEW ZEALAND, JAPAN, SINGAPORE, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

The final results of Martela Corporation’s (“Martela” or the “Company”) directed share issue (the “Share Issue”) show that a total of 15,907,707 subscriptions for new shares of the Company corresponding to the existing series A shares, representing the Company’s sole series of shares following the combination of share series (the “Offer Shares“) were made in the Share Issue, corresponding to approximately 89 per cent of the 17,777,777 Offer Shares offered in the Share Issue. The subscription price in the Share Issue was EUR 0.45 per Offer Share. Martela receives gross proceeds of approximately EUR 7.2 million from the Share Issue.

Martela’s Board of Directors has today approved the subscriptions made in the Share Issue, and allocated the Offer Shares to be issued, in accordance with the terms and conditions of the Share Issue. As a result of the Share Issue and the combination of share series and the related directed share issue without consideration, as previously disclosed by the Company, the total number of shares in Martela will increase by a maximum of 16,058,907 from 4,639,212 to a maximum of 20,698,119 provided that the combination of the Company’s share series is registered with the Trade Register and the directed share issue without consideration is carried out at its maximum amount, i.e. 151,200 shares. The Offer Shares issued in the Share Issue amount to approximately 77 per cent of all shares in Martela following the Share Issue provided that the combination of share series is registered with the Trade Register.

The Offer Shares will be registered with the Finnish Trade Register maintained by the Finnish Patent and Registration Office on or about 12 October 2026. Trading in the Offer Shares on Nasdaq Helsinki Ltd is estimated to commence on 13 October 2026. The Offer Shares carry the right to dividends and other shareholder rights once the Offer Shares have been registered with the Trade Register. Following the registration of the combination of the share series with the Trade Register on or about 12 October 2026, the Offer Shares carry the same rights as the Company’s other shares.

Advisors

Aktia Alexander Corporate Finance Oy is acting as Martela’s financial advisor and as the Lead Manager of the Share Issue. Castrén & Snellman Attorneys Ltd is acting as Martela’s legal advisor.

MARTELA CORPORATION
BOARD OF DIRECTORS

FOR FURTHER INFORMATION, PLEASE CONTACT:

CEO, Panu Ala-Nikkola
tel +358 50 502 4728

CFO, Henri Berg
tel +358 40 836 5464

Chairman of the Board, Tapio Pajuharju
tel +358 50 5774 200

DISTRIBUTION:

NASDAQ Helsinki, key news media, www.martela.com

MARTELA CORPORATION:

Martela is a Nordic leader specialising in user-centric working and learning environments. With over 80 years of experience, we create the best places to work and offer our customers the Martela Lifecycle solutions which combine furniture and related services into a seamless whole.

IMPORTANT NOTICE:

The distribution of this release may be restricted by law and persons into whose possession any document or other information referred to herein comes should inform themselves about and observe any such relevant legal restrictions. The information contained herein is not for release, publication or distribution, directly or indirectly, in or into the United States, Australia, Canada, Hong Kong, New Zealand, Japan, Singapore, South Africa or any other jurisdiction in which the release, publication or distribution would be unlawful. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction. This release is not directed to, and is not intended for release, publication or distribution to or use by, any person or entity that is a citizen or resident of, or is located in, any locality, state, country or other jurisdiction where such release, distribution, publication, availability or use would violate law or regulation or which would require any registration or licensing within such jurisdiction.

This release does not constitute a prospectus as defined in the Prospectus Regulation nor a document containing the information set out in Annex IX of the Prospectus Regulation and, as such, it does not constitute or form part of, and should not be construed as, an offer to sell, or a solicitation or invitation of any offer to buy, acquire or subscribe for, any securities or an inducement to enter into investment activity in relation to any securities.

No part of this release, nor the fact of its release, publication or distribution, should form the basis of, or be relied on in connection with, any contract or commitment or investment decision whatsoever. No representation, warranty or undertaking, expressed or implied, is made as to, and no reliance should be placed on, the pertinence, accuracy, completeness or correctness of the information or the opinions contained herein. Neither the Company nor any of its respective affiliates, advisors or representatives or any other person shall have any liability whatsoever (in negligence or otherwise) for any loss, however arising, from any use of this release or its contents or otherwise arising in connection with this release. Each person must rely on their own examination and analysis of the Company, its subsidiaries, its securities and the transactions, including the merits and risks involved.

Aktia Alexander Corporate Finance Oy acts exclusively for the Company and no one else in connection with the arrangement. Aktia Alexander Corporate Finance Oy does not regard any other person as its client in relation to the arrangement. Aktia Alexander Corporate Finance Oy is not responsible to anyone other than the Company for providing the protections afforded to its clients, nor for giving advice in relation to the arrangement or any transaction or arrangement referred to herein.

This release includes forward-looking statements. These statements may not be based on historical facts, but are statements about future expectations. When used in this release, the words “aims,” “anticipates,” “assumes,” “believes,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “should,” “will,” “would” and similar expressions as they relate to the Company and the transactions identify certain of these forward-looking statements. Other forward-looking statements can be identified in the context in which the statements are made. These forward-looking statements are based on present plans, estimates, projections and expectations and are not guarantees of future performance. They are based on certain expectations, which, even though they seem to be reasonable at present, may turn out to be incorrect. Such forward-looking statements are based on assumptions and are subject to various risks and uncertainties. Readers should not rely on these forward-looking statements. Numerous factors may cause the actual results of operations or financial condition of the Company to differ materially from those expressed or implied in the forward-looking statements. Neither the Company nor any of its affiliates, advisors, representatives or any other person undertakes any obligation to review, confirm or to publicly release any revisions to any forward-looking statements to reflect events that occur or circumstances that arise following the date of this release.

Debuts at Innovation Forum to Record Attendance 

CHICAGO and LONDON, Oct. 06, 2026 (GLOBE NEWSWIRE) — Descartes Systems Group (Nasdaq:DSGX) (TSX:DSG), the global leader in uniting logistics-intensive businesses in commerce, introduced the Descartes Agent Control Plane at its Innovation Forum in Chicago, which this year brings together a record number of customers, speakers and sponsors to explore innovation in supply chain and logistics technology. Built on the Descartes Global Logistics Network™ (Descartes GLN™), the Agent Control Plane is designed to build trust in AI agents by coordinating them across applications and trading partners to execute multi-step workflows within defined guardrails, policies and human oversight.

“Even with connected systems, supply chain teams devote significant time to interpreting updates from emails, messages and portals, rekeying information and coordinating next steps to move orders forward,” said Ken Wood, Executive Vice President, Product Management at Descartes. “The Agent Control Plane brings our logistics capabilities together so AI agents can take on more of that work across applications, conversations and company boundaries; keep it moving as replies and approvals arrive; and act on events as they occur within permissions and approval points defined by customers. It’s an important step in our AI strategy, helping customers build on the Descartes solutions and AI platforms they already use and apply AI to the operational outcomes that matter, from reducing manual follow-up to keeping customer commitments on track.”

The Agent Control Plane combines the operationally ready data and connectivity of the Descartes GLN with capabilities from Descartes solutions to help AI agents coordinate work across applications and trading partners, and to make Descartes agents available within the AI platforms customers already use. The GLN supplies the logistics context to connect changes in one part of a shipment’s journey with actions needed elsewhere, while the Agent Control Plane applies customer-defined permissions and approvals and maintains a traceable record of agent actions. Together, they help reduce manual handoffs, accelerate responses to changing conditions and give teams more time to focus on exceptions and customer relationships.

“We’re pleased to welcome such a strong community of customers, sponsors and speakers to this year’s Innovation Forum,” said Edward J. Ryan, CEO at Descartes. “Record participation reflects the value of bringing this community together to share experiences, learn from one another and explore new possibilities. The conversations we have here help us understand our customers’ priorities and shape how we continue to innovate in support of their success.”

Bringing together 1,000+ attendees and 200+ speakers this year, the three-day Innovation Forum features sessions across fleet performance management, transportation management, global trade intelligence, logistics service providers and ecommerce operations. Industry and customer presentations, discussions with Descartes product specialists and hands-on demonstrations at the Technology Fair give attendees opportunities to explore practical ways to improve operations and gain more value from their technology investments.

To learn more about event speakers, sessions and sponsors, visit www.descartes.com/innovation-forum.

About Descartes

Descartes powers more responsive, efficient, secure and sustainable international and domestic supply chains by uniting logistics-intensive businesses on its Global Logistics Network (GLN). Shippers, carriers, and logistics service providers connect and collaborate on the GLN leveraging technology, data and AI to manage last mile deliveries, domestic and international shipments, transportation rating and payment, global trade research, customs compliance and a variety of regulatory processes. Learn more about Descartes at www.descartes.com and connect with us on LinkedIn and X.

Global Media Contact
Cara Strohack
Tel: 226-750-8050
cstrohack@descartes.com

Cautionary Statement Regarding Forward-Looking Statements

This release contains forward-looking information within the meaning of applicable securities laws (“forward-looking statements”) that relate to Descartes’ logistics and supply chain solution offerings and potential benefits derived therefrom; the innovations Descartes intends to present at its Innovation Forum in Chicago; and other matters. Such forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, performance or achievements to differ materially from the anticipated results, performance or achievements or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the factors and assumptions discussed in the section entitled, “Certain Factors That May Affect Future Results” in documents filed with the Securities and Exchange Commission, the Ontario Securities Commission and other securities regulatory authorities across Canada including Descartes’ most recently filed annual and interim management’s discussion and analysis which are available under Descartes’ profile through the EDGAR website at http://www.sec.gov or through the SEDAR+ website at http://www.sedarplus.com/. If any such risks actually occur, they could, among other consequences, materially adversely affect our business, financial condition or results of operations. In that case, the trading price of our common shares could decline, perhaps materially. Readers are cautioned not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Forward-looking statements are provided for the purposes of providing information about management’s current expectations and plans relating to the future. Readers are cautioned that such information may not be appropriate for other purposes. Except as required by applicable law, Descartes undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise.

Debuts at Innovation Forum to Record Attendance 

CHICAGO and LONDON, Oct. 06, 2026 (GLOBE NEWSWIRE) — Descartes Systems Group (Nasdaq:DSGX) (TSX:DSG), the global leader in uniting logistics-intensive businesses in commerce, introduced the Descartes Agent Control Plane at its Innovation Forum in Chicago, which this year brings together a record number of customers, speakers and sponsors to explore innovation in supply chain and logistics technology. Built on the Descartes Global Logistics Network™ (Descartes GLN™), the Agent Control Plane is designed to build trust in AI agents by coordinating them across applications and trading partners to execute multi-step workflows within defined guardrails, policies and human oversight.

“Even with connected systems, supply chain teams devote significant time to interpreting updates from emails, messages and portals, rekeying information and coordinating next steps to move orders forward,” said Ken Wood, Executive Vice President, Product Management at Descartes. “The Agent Control Plane brings our logistics capabilities together so AI agents can take on more of that work across applications, conversations and company boundaries; keep it moving as replies and approvals arrive; and act on events as they occur within permissions and approval points defined by customers. It’s an important step in our AI strategy, helping customers build on the Descartes solutions and AI platforms they already use and apply AI to the operational outcomes that matter, from reducing manual follow-up to keeping customer commitments on track.”

The Agent Control Plane combines the operationally ready data and connectivity of the Descartes GLN with capabilities from Descartes solutions to help AI agents coordinate work across applications and trading partners, and to make Descartes agents available within the AI platforms customers already use. The GLN supplies the logistics context to connect changes in one part of a shipment’s journey with actions needed elsewhere, while the Agent Control Plane applies customer-defined permissions and approvals and maintains a traceable record of agent actions. Together, they help reduce manual handoffs, accelerate responses to changing conditions and give teams more time to focus on exceptions and customer relationships.

“We’re pleased to welcome such a strong community of customers, sponsors and speakers to this year’s Innovation Forum,” said Edward J. Ryan, CEO at Descartes. “Record participation reflects the value of bringing this community together to share experiences, learn from one another and explore new possibilities. The conversations we have here help us understand our customers’ priorities and shape how we continue to innovate in support of their success.”

Bringing together 1,000+ attendees and 200+ speakers this year, the three-day Innovation Forum features sessions across fleet performance management, transportation management, global trade intelligence, logistics service providers and ecommerce operations. Industry and customer presentations, discussions with Descartes product specialists and hands-on demonstrations at the Technology Fair give attendees opportunities to explore practical ways to improve operations and gain more value from their technology investments.

To learn more about event speakers, sessions and sponsors, visit www.descartes.com/innovation-forum.

About Descartes

Descartes powers more responsive, efficient, secure and sustainable international and domestic supply chains by uniting logistics-intensive businesses on its Global Logistics Network (GLN). Shippers, carriers, and logistics service providers connect and collaborate on the GLN leveraging technology, data and AI to manage last mile deliveries, domestic and international shipments, transportation rating and payment, global trade research, customs compliance and a variety of regulatory processes. Learn more about Descartes at www.descartes.com and connect with us on LinkedIn and X.

Global Media Contact
Cara Strohack
Tel: 226-750-8050
cstrohack@descartes.com

Cautionary Statement Regarding Forward-Looking Statements

This release contains forward-looking information within the meaning of applicable securities laws (“forward-looking statements”) that relate to Descartes’ logistics and supply chain solution offerings and potential benefits derived therefrom; the innovations Descartes intends to present at its Innovation Forum in Chicago; and other matters. Such forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, performance or achievements to differ materially from the anticipated results, performance or achievements or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the factors and assumptions discussed in the section entitled, “Certain Factors That May Affect Future Results” in documents filed with the Securities and Exchange Commission, the Ontario Securities Commission and other securities regulatory authorities across Canada including Descartes’ most recently filed annual and interim management’s discussion and analysis which are available under Descartes’ profile through the EDGAR website at http://www.sec.gov or through the SEDAR+ website at http://www.sedarplus.com/. If any such risks actually occur, they could, among other consequences, materially adversely affect our business, financial condition or results of operations. In that case, the trading price of our common shares could decline, perhaps materially. Readers are cautioned not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Forward-looking statements are provided for the purposes of providing information about management’s current expectations and plans relating to the future. Readers are cautioned that such information may not be appropriate for other purposes. Except as required by applicable law, Descartes undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise.

CALGARY, Alberta, Oct. 06, 2026 (GLOBE NEWSWIRE) — Marvel Biosciences Corp. (TSXV: MRVL | OTCQB: MBCOF), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), a drug discovery company developing novel therapeutics for autism spectrum disorder (“ASD”) and related neurodevelopmental disorders, is pleased to announce it has signed a letter of intent with Novatech, widely recognized as the premier Asia-Pacific (APAC) full-service clinical CRO for small to mid-sized biotech and pharmaceutical companies.

The signing of the LOI marks an important development milestone for Marvel as MB-204 advances from preclinical development toward first-in-human clinical evaluation. The planned Phase 1 program is designed to establish the initial safety, tolerability and pharmacokinetic profile of MB-204 in humans, while generating clinical data to inform subsequent development. This transition is supported by encouraging preclinical findings, with MB-204 demonstrating immediate, robust and durable effects, including measurable carry-over effects following cessation of treatment, across multiple mouse models relevant to neurodevelopmental disorders, including Oprm1, Rett and Fragile X models. Together, these findings provide a scientific rationale for advancing MB-204 into clinical development and establishing its initial human safety and pharmacokinetic profile.

“We are pleased to begin moving forward into a Phase I trial for MB-204 in partnership with Novatech following the recent closing of our private placement and signing of a letter-of-intent,” said Marvel’s CEO Rod Matheson. “Novatech provides end-to-end clinical trial management, site selection, regulatory and ethics submissions, biostatistics, data management, and medical writing. They have an early-phase clinical focus including First-in-Human and proof-of-concept studies. The trial will be conducted in Australia which offers a streamlined and favourable regulatory environment as well as a generous 43% tax credit. We look forward to updating the market on our single ascending dose and multiple ascending dose studies as we progress. This marks Marvel’s transition from a pre-clinical to clinical phase company.”

Corporate Update:

• The Phase I single ascending dose (SAD) study is expected to begin in Q4 of 2026. The SAD study is designed to test the safety, tolerability and pharmacokinetics (PK) of MB-204 as well as include a potential biomarker and several cognitive endpoints. The data from the SAD will inform the design of the subsequent multiple ascending dose (MAD) study.
• Marvel has previously developed a novel liquid-based formulation of MB-204 for its Phase 1 trial SAD study which improved the drug’s PK in pre-clinical studies and may facilitate administration in patient populations where swallowing solid dosage forms may present challenges. The work was conducted with a grant from the National Research Council of Canada.
• The Company is currently preparing manuscripts for scientific publication and will provide a future update on conference participation.
• In collaboration with the iBrain Inserm Lab, Marvel is planning an upcoming experiment to test the efficacy of MB-204 against Yamo Pharmaceuticals’ L1-79 (repurposed racemic N-methyl Tyrosine) in a mouse model of autism. L1-79 recently demonstrated efficacy in a Phase 2 study.

About Marvel Biosciences Corp.

Marvel Biosciences Corp. (TSXV:MRVL | OTCQB:MBCOF), and its wholly-owned subsidiary, Marvel Biotechnology Inc., is a Calgary-based pharmaceutical development biotechnology company entering Phase 1 clinical stage. The Company is developing MB-204, a novel fluorinated derivative of the approved anti-Parkinson’s drug Istradefylline, the only clinically approved adenosine A2a antagonist. A significant and growing body of scientific evidence suggests drugs that block the adenosine A2a receptor, such as MB-204, could be useful in treating other neurological diseases such as autism, depression and Alzheimer’s Disease. The Company is actively investigating its potential in addressing other neurodevelopmental disorders, such as Rett Syndrome and Fragile X Syndrome, to expand its therapeutic reach.

Contact Information: Marvel Biosciences Corp.
J. Roderick (Rod) Matheson, Chief Executive Officer
Email: rod@marvelbiosciences.com
Dr. Mark Williams, President and Chief Science Officer
Email: mark@marvelbiosciences.com
Tel: 403 770 2469Website: www.marvelbiotechnology.com    |   Twitter/X   |   LinkedIn

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release. All information contained in this news release with respect to the Company and its subsidiary,(collectively, the “Parties”) were supplied by Marvel, respectively, for inclusion herein and each parties’ directors and officers have relied on each other for any information concerning such Party.

This news release may contain forward-looking statements and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the future plans and objectives of the Company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the expectations of the Company and include other risks detailed from time to time in the filings made by the Company under securities regulations.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. As a result, the Company cannot guarantee that the above events on the terms will occur and within the time disclosed herein or at all. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by Canadian securities law.

CALGARY, Alberta, Oct. 06, 2026 (GLOBE NEWSWIRE) — Marvel Biosciences Corp. (TSXV: MRVL | OTCQB: MBCOF), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), a drug discovery company developing novel therapeutics for autism spectrum disorder (“ASD”) and related neurodevelopmental disorders, is pleased to announce it has signed a letter of intent with Novatech, widely recognized as the premier Asia-Pacific (APAC) full-service clinical CRO for small to mid-sized biotech and pharmaceutical companies.

The signing of the LOI marks an important development milestone for Marvel as MB-204 advances from preclinical development toward first-in-human clinical evaluation. The planned Phase 1 program is designed to establish the initial safety, tolerability and pharmacokinetic profile of MB-204 in humans, while generating clinical data to inform subsequent development. This transition is supported by encouraging preclinical findings, with MB-204 demonstrating immediate, robust and durable effects, including measurable carry-over effects following cessation of treatment, across multiple mouse models relevant to neurodevelopmental disorders, including Oprm1, Rett and Fragile X models. Together, these findings provide a scientific rationale for advancing MB-204 into clinical development and establishing its initial human safety and pharmacokinetic profile.

“We are pleased to begin moving forward into a Phase I trial for MB-204 in partnership with Novatech following the recent closing of our private placement and signing of a letter-of-intent,” said Marvel’s CEO Rod Matheson. “Novatech provides end-to-end clinical trial management, site selection, regulatory and ethics submissions, biostatistics, data management, and medical writing. They have an early-phase clinical focus including First-in-Human and proof-of-concept studies. The trial will be conducted in Australia which offers a streamlined and favourable regulatory environment as well as a generous 43% tax credit. We look forward to updating the market on our single ascending dose and multiple ascending dose studies as we progress. This marks Marvel’s transition from a pre-clinical to clinical phase company.”

Corporate Update:

• The Phase I single ascending dose (SAD) study is expected to begin in Q4 of 2026. The SAD study is designed to test the safety, tolerability and pharmacokinetics (PK) of MB-204 as well as include a potential biomarker and several cognitive endpoints. The data from the SAD will inform the design of the subsequent multiple ascending dose (MAD) study.
• Marvel has previously developed a novel liquid-based formulation of MB-204 for its Phase 1 trial SAD study which improved the drug’s PK in pre-clinical studies and may facilitate administration in patient populations where swallowing solid dosage forms may present challenges. The work was conducted with a grant from the National Research Council of Canada.
• The Company is currently preparing manuscripts for scientific publication and will provide a future update on conference participation.
• In collaboration with the iBrain Inserm Lab, Marvel is planning an upcoming experiment to test the efficacy of MB-204 against Yamo Pharmaceuticals’ L1-79 (repurposed racemic N-methyl Tyrosine) in a mouse model of autism. L1-79 recently demonstrated efficacy in a Phase 2 study.

About Marvel Biosciences Corp.

Marvel Biosciences Corp. (TSXV:MRVL | OTCQB:MBCOF), and its wholly-owned subsidiary, Marvel Biotechnology Inc., is a Calgary-based pharmaceutical development biotechnology company entering Phase 1 clinical stage. The Company is developing MB-204, a novel fluorinated derivative of the approved anti-Parkinson’s drug Istradefylline, the only clinically approved adenosine A2a antagonist. A significant and growing body of scientific evidence suggests drugs that block the adenosine A2a receptor, such as MB-204, could be useful in treating other neurological diseases such as autism, depression and Alzheimer’s Disease. The Company is actively investigating its potential in addressing other neurodevelopmental disorders, such as Rett Syndrome and Fragile X Syndrome, to expand its therapeutic reach.

Contact Information: Marvel Biosciences Corp.
J. Roderick (Rod) Matheson, Chief Executive Officer
Email: rod@marvelbiosciences.com
Dr. Mark Williams, President and Chief Science Officer
Email: mark@marvelbiosciences.com
Tel: 403 770 2469Website: www.marvelbiotechnology.com    |   Twitter/X   |   LinkedIn

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release. All information contained in this news release with respect to the Company and its subsidiary,(collectively, the “Parties”) were supplied by Marvel, respectively, for inclusion herein and each parties’ directors and officers have relied on each other for any information concerning such Party.

This news release may contain forward-looking statements and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the future plans and objectives of the Company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the expectations of the Company and include other risks detailed from time to time in the filings made by the Company under securities regulations.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. As a result, the Company cannot guarantee that the above events on the terms will occur and within the time disclosed herein or at all. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by Canadian securities law.

GEORGE TOWN, Cayman Islands, Oct. 06, 2026 (GLOBE NEWSWIRE) — Bullish (NYSE: BLSH), an institutionally focused global digital asset platform that provides market infrastructure and information services, released its monthly metrics for September 2026 on Tuesday, October 6, 2026.

These metrics include trading volume, average trading spread, and measures of volatility for Bitcoin and Ethereum. For definitions and additional information regarding these metrics, please refer to the monthly metrics packages available on investors.bullish.com.

About Bullish

Bullish (NYSE: BLSH) is an institutionally focused global digital asset platform that provides regulated market infrastructure and information services. This includes Bullish Exchange – an institutionally focused digital assets spot and derivatives exchange, integrating a high-performance central limit order book matching engine with automated market making to provide deep and predictable liquidity. Bullish Europe is regulated under MiCAR as a crypto asset service provider offering spot trading and custody services for digital assets.

Bullish is the parent company of CoinDesk, a leading provider of digital asset media and information services. CoinDesk’s offerings include: CoinDesk Indices – a collection of tradable proprietary and single-asset benchmarks and indices that track the performance of digital assets for global institutions in the digital assets and traditional finance industries; CoinDesk Data – a broad suite of digital asset market data and analytics, providing real-time insights into prices, trends and market dynamics; and CoinDesk Insights – a digital asset media and events provider and operator of coindesk.com, a digital media platform that covers news and insights about digital assets, the underlying markets, policy and blockchain technology.

For more information, please visit bullish.com and follow LinkedIn and X.

Use of Websites to Distribute Material Company Information

We use the Bullish Investor Relations website (investors.bullish.com) and our X account (x.com/bullish) to publicize information relevant to investors, including information that may be deemed material, in addition to filings we make with the U.S. Securities and Exchange Commission (SEC) and press releases. We encourage investors to regularly review the information posted on our website and X account in addition to our SEC filings and press releases to be informed of the latest developments.

Contacts

Media: media@bullish.com

Investor Relations: investors@bullish.com

Source: Bullish

Additional Information & Disclosures

This monthly metrics package provides certain limited purpose monthly performance results of Bullish. This information is presented without commentary and should be read together with our most recent quarterly and annual results and our filings with the U.S. Securities and Exchange Commission (SEC), which are available on our Investor Relations website at investors.bullish.com.

The information provided is unaudited and the information for the months in the most recent fiscal quarter is preliminary, based on our estimates and subject to completion of our financial closing procedures. Final results for the quarter, as reported in our SEC filings, might vary from the information provided in this monthly metrics package.

Bullish expects to release monthly metrics packages for the prior month’s performance after the end of each month.

We use our Investor Relations website (investors.bullish.com) and our X account (x.com/bullish) to publicize information relevant to investors, including information that may be deemed material, in addition to filings we make with the SEC and press releases. We encourage investors to regularly review the information posted on our website and X account in addition to our SEC filings and press releases to be informed of the latest developments.

Definitions

Trading Volume represents the notional value of trades, i.e. the product of the quantity of assets transacted and the trade price at the time the transaction was executed. The quantity represents the total U.S. dollar equivalent value of matched trades transacted between a buyer and seller through our platform during the period of measurement.

Average Trading Spread represents total commissions earned from transactions on the Bullish Exchange for the period, expressed as a percentage of the trading volume for the period. Management reviews this metric, which reflects the cost of trading on the Bullish Exchange, changes in fair value of perpetual futures, and rebates, for insight into the average revenue generated per unit of trading volume on our platform.

Volatility is calculated using 1-minute price intervals from Coindesk Data’s Adaptive Diversified Liquidity Index for BTC and ETH. We determine the daily volatility by measuring the standard deviation of these minute-by-minute price changes, which provides a more granular view of price fluctuations. This daily figure is then converted to an annualized volatility by multiplying it by the square root of 365, a standard practice for making risk metrics comparable over a one-year period.

Monthly Metrics Report for September 2026
(Unaudited)
	2025													2026
	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec		Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep
(B – in billions)
Trading Volume ($B)
Spot – BTC	34.6	30.9	43.2	39.2	32.8	19.9	20.8	18.2	16.4	38.2	38.4	25.9		22.5	41.8	29.1	20.9	16.8	26.9	16.7	17.6	19.9
Spot – ETH	18.3	19.2	14.9	10.9	12.0	9.5	11.1	12.8	8.8	15.1	14.1	9.6		8.4	12.9	8.0	5.4	3.4	4.9	3.0	3.7	4.5
Spot – Stablecoin	19.4	20.9	17.0	13.3	10.3	8.1	12.9	8.6	8.1	19.6	18.4	13.8		11.2	19.0	13.2	9.6	7.4	10.8	7.3	7.9	9.5
Spot – Other	4.8	3.8	2.7	2.2	2.6	2.4	4.0	4.6	4.1	4.6	4.4	2.9		3.4	3.7	2.7	2.1	2.5	2.9	2.2	6.6	8.4
Total Spot	77.1	74.8	77.7	65.5	57.6	39.9	48.8	44.3	37.3	77.5	75.3	52.2		45.4	77.4	52.9	38.0	30.0	45.5	29.1	35.8	42.2
Options								0.0	0.0	0.0	2.8	6.2		4.8	3.6	3.2	5.6	0.9	2.3	0.2	4.7	4.1
Perpetual	6.6	7.8	8.0	6.8	5.8	4.1	5.0	4.6	2.2	3.0	2.7	2.6		2.0	3.1	4.4	3.4	2.0	3.1	1.5	2.0	2.3
Total Trading Volume	83.7	82.5	85.7	72.3	63.4	44.0	53.8	48.8	39.6	80.5	80.8	61.1		52.2	84.1	60.4	46.9	32.9	50.9	30.7	42.5	48.6
Average Trading Spread (bps)
Spot	2.14	1.97	1.87	1.65	1.55	1.58	1.76	2.55	1.96	1.75	1.94	1.82		1.74	2.22	2.01	2.05	2.40	2.84	2.71	2.53	2.41
Options								1.00	0.93	1.29	1.34	1.66		1.95	2.42	1.86	2.50	1.65	0.59	1.09	0.14	0.40
Perpetual	(1.06)	(1.41)	(2.38)	(1.47)	(0.86)	(1.22)	(0.80)	(0.65)	0.21	(2.67)	(0.13)	(0.30)		(0.61)	0.37	0.09	(0.08)	(0.12)	(0.14)	1.21	(0.32)	0.38
Average Trading Spread	1.90	1.65	1.47	1.36	1.32	1.32	1.52	2.25	1.86	1.59	1.85	1.71		1.67	2.16	1.86	1.95	2.23	2.56	2.62	2.13	2.14
Monthly Average Volatility
BTC	48%	44%	50%	44%	33%	28%	27%	28%	23%	38%	45%	39%		33%	61%	48%	35%	28%	47%	32%	30%	32%
ETH	60%	78%	69%	70%	67%	54%	54%	60%	42%	58%	68%	53%		46%	82%	60%	44%	36%	67%	44%	39%	42%
* Figures presented may not sum precisely due to rounding